Pilar M. Moreno-Sanchez

Pilar M. Moreno-Sanchez

Auto-generated profile, based on publicly available information

Pilar M. Moreno-Sanchez

NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
PMPilar M. Moreno-Sanchez
Pilar M. Moreno-Sanchez
MRMahsa Rezaeipour
Mahsa Rezaeipour
EIElse Marit Inderberg
Else Marit Inderberg
MPMichael Platten
Michael Platten
Anna GolebiewskaAnna Golebiewska
Anna Golebiewska

9 April 2021 in Genes
Verified
Journal Article
Open access
PDF file
RERicardo Errazquin
Ricardo Errazquin
ESEsther Sieiro
Esther Sieiro
PMPilar Moreno
Pilar Moreno
MRMaría José Ramirez
María José Ramirez
CLCorina Lorz
Corina Lorz
RGRamon Garcia-Escudero
Ramon Garcia-Escudero
Fanconi anemia (FA) patients have an exacerbated risk of head and neck squamous cell carcinoma (HNSCC). Treatment is challenging as FA patients display enhanced toxicity to standard treatments, including radio/chemotherapy. Therefore, better therapies as well as new disease models are urgently needed. We have used CRISPR/Cas9 editing tools in order to interrupt the human FANCA gene by the generation of insertions/deletions (indels) in exon 4 in two cancer cell lines from sporadic HNSCC having no mutation in FA-genes: CAL27 and CAL33 cells. Our approach allowed efficient editing, subsequent purification of single-cell clones, and Sanger sequencing validation at the edited locus. Clones having frameshift indels in homozygosis did not express FANCA protein and were selected for further analysis. When compared with parental CAL27 and CAL33, FANCA-mutant cell clones displayed a FA-phenotype as they (i) are highly sensitive to DNA interstrand crosslink (ICL) agents such as mitomycin C (MMC) or cisplatin, (ii) do not monoubiquitinate FANCD2 upon MMC treatment and therefore (iii) do not form FANCD2 nuclear foci, and (iv) they display increased chromosome fragility and G2 arrest after diepoxybutane (DEB) treatment. These FANCA-mutant clones display similar growth rates as their parental cells. Interestingly, mutant cells acquire phenotypes associated with more aggressive disease, such as increased migration in wound healing assays. Therefore, CAL27 and CAL33 cells with FANCA mutations are phenocopies of FA-HNSCC cells.


21 November 2025 in bioRxiv
Verified
Preprint
Open access
PMPilar M. Moreno-Sanchez
Pilar M. Moreno-Sanchez
AOAnaïs Oudin
Anaïs Oudin
BKBatuhan Kisakol
Batuhan Kisakol
HDHeiko Dussmann
Heiko Dussmann
EKEliane Klein
Eliane Klein
Anna GolebiewskaAnna Golebiewska
Anna Golebiewska
Immune-based strategies have so far failed to demonstrate clinical benefit in glioblastoma (GBM), largely due to the profound immunosuppressive tumor microenvironment (TME). To achieve more predictive preclinical insights, advanced in vivo models that faithfully recapitulate the human brain immune landscape are urgently needed. Here, we established GBM patient-derived orthotopic xenografts (PDOXs) across diverse mouse strains, including humanized models. Humanization was achieved through transplantation of CD34 + hematopoietic stem cells (HU-CD34 + ) or peripheral blood mononuclear cells (HU-PBMC). Both models successfully reconstituted human T-cells systemically, with stronger engraftment in HU-CD34 + mice. We observed selective infiltration and spatial organization to intracranial GBM tumors, including exhausted, memory-like, and regulatory CD4 + T-cell phenotypes, TIM-3 + immunosuppressive-like myeloid cells and intratumoral B cells. Mouse microglia-derived tumor-associated macrophages (TAMs) remained the dominant immunosuppressive immune population. Anti-PD-1 therapy, but not anti-GITR, modestly modulated the infiltration dynamics, demonstrating the susceptibility of the reconstructed adaptive immunity to immunotherapeutic intervention. These findings position humanized GBM PDOXs as a relevant preclinical platform to interrogate tumor-immune interactions and evaluate immunotherapeutic strategies in a human context. Key points: GBM PDOXs developed in HU-CD34 + and HU-PBMC mice faithfully reconstitute systemic and local human adaptive immunity. Human immune components undergo selective infiltration, spatial organization and transition towards exhausted CD4 + T-cells and immunosuppressive CD11c + myeloid cells. Anti-PD-1, but not anti-GITR, locally promote human immune infiltration into intracranial GBM tumors, while sparing systemic compartments. Humanized GBM PDOXs provide a powerful preclinical platform to test novel immunotherapeutic strategies. Study importance: Immune checkpoint blockade has shown limited efficacy in GBM, reflecting the highly immunosuppressive and lymphocyte-poor nature of the TME. Conventional syngeneic and GEMM models fail to recapitulate these features, contributing to the translational disconnect between preclinical success and clinical failure. Humanized mice provide a solution to interrogate human-specific immunity in vivo , but their use in GBM has remained limited. Here, we provide the first comparison of GBM PDOX modeling in two complementary modes of humanization based on CD34 + HSCs and PBMCs. We systematically profile systemic and intratumoral compartments, showing that these models faithfully reconstitute human adaptive immunity and capture the interplay with the murine brain TME. Furthermore, we demonstrate clinically-relevant responses upon treatment with checkpoint antibodies targeting PD-1 and GITR, showing modulation of human immune subsets without altering murine TAM immunosuppression, underscoring the translational value of the system. This study establishes humanized GBM PDOXs as a versatile platform for dissecting tumor-immune interactions in the brain and for preclinical evaluation and development of novel immunotherapies. Graphical

11 September 2026 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
MRMahsa Rezaeipour
Mahsa Rezaeipour
MSMarta de Lucas Sanz
Marta de Lucas Sanz
HAHamed Allahverdi
Hamed Allahverdi
GTGaëlle Triballier
Gaëlle Triballier
EKEliane Klein
Eliane Klein
Anna GolebiewskaAnna Golebiewska
Anna Golebiewska
Introduction: Glioblastoma represents an aggressive, immunologically cold primary brain tumor largely unresponsive to conventional immunotherapies. Dissecting patient-specific immunosuppressive cues is limited by current preclinical models. Understanding the functional cross-talk between tumor and immune cells across distinct microenvironmental niches is crucial for advancing personalized immunotherapy. Methods: We assessed the immunogenic features of glioblastoma cells and cross-talk with T-cells using bulk and single-cell RNA-seq, multicolor flow cytometry, immunohistochemistry, and functional assays in patient tumors, patient-derived organoids (PDOs), orthotopic xenografts and cell cultures. We developed an advanced 3D co-culture system combining PDOs with human peripheral blood T-cells isolated from glioblastoma patients or healthy donor blood to functionally investigate T-cell behavior in a patient-specific context. T-cell subsets integrated and non-integrated into the PDOs were examined for T-cell activation, exhaustion, and T regulatory cell development in response to tumor-derived signals and hypoxia. Results: Single-cell RNA-seq-based crosstalk predicted direct ligand-receptor and soluble axes between glioblastoma and T-cells. Glioblastoma cells in patient tumors and diverse patient-derived models showed cell surface MHC class I expression across diverse genetic backgrounds and microenvironmental niches, modulable by interferon gamma. Subsets of CD4 + and CD8 + T-cells integrated into 3D PDOs deprived of myeloid component. PDO-integrated T-cells were enriched for T regulatory cells (Treg), and exhibited a heterogeneous spectrum of activation and dysfunction states, with differential expression of PD-1, LAG-3, TIM-3, CD45RO, Granzyme B, TCF1, and TOX. T-cells subjected to soluble factors were largely unaffected and retained capacity to reintegrate PDOs at sequential co-cultures. Hypoxia influenced T-cell phenotype, but did not prevent activation or infiltration within the early stages of co-culture. Conclusion: Our work provides insights into tumor-intrinsic cues of immune evasion in glioblastoma and introduces a scalable patient-relevant ex vivo platform for functional studies. Surface MHC-I was detectable in all assessed glioblastoma models; and was retained in contact with T-cells, indicating that MHC-I loss is not their predominant immune-escape mechanism. Immunosuppression occurred in direct contact with glioblastoma cells, involving both TOX-dependent exhaustion and TOX-independent dysfunction. Advanced co-cultures of glioblastoma PDOs may serve as a powerful tool for functional studies ex vivo, predicting clinically-relevant responses to immunotherapeutic treatments in the future.